본문 바로가기

EU · EudraLex Vol.4

EU GMP Annex 1 9.46

9. Environmental & process monitoring › Aseptic process simulation (APS) (also known as media fill)

조항 원문

The target should be zero growth. Any contaminated unit should result in a failed APS and the following actions should be taken:

i. An investigation to determine the most probable root cause(s).

ii. Determination and implementation of appropriate corrective measures.

iii. A sufficient number of successful, consecutive repeat APS (normally a minimum of 3) should be conducted in order to demonstrate that the process has been returned to a state of control.

iv. A prompt review of all appropriate records relating to aseptic production since the last successful APS.

a) The outcome of the review should include a risk assessment of potential sterile breaches in batches manufactured since the last successful APS.

b) All other batches not released to the market should be included in the scope of the investigation. Any decision regarding their release status should consider the investigation outcome.

v. All products that have been manufactured on a line subsequent to a process simulation failure should be quarantined until a successful resolution of the process simulation failure has occurred.

vi. Where the root cause investigation indicates that the failure was related to operator activity, actions to limit the operator’s activities, until retrained and requalified, should be taken.

vii. Production should resume only after completion of successful revalidation.

본문은 원문(영어)입니다. 국문 번역은 준비 중입니다.

출처: European Commission, DG SANTE · © European Union. Reuse is authorised provided the source is acknowledged (Commission Decision 2011/833/EU on the reuse of Commission documents). · 수집일 2026-11-15

Weekly Newsletter

이런 지적, 매주 월요일 한국어로 받아보세요

FDA·EMA·식약처의 새 지적과 조치를 공식 원문 링크와 함께 보내드립니다. 사이트에 새로운 기능이 생기면 함께 안내드립니다. 구독은 언제든 한 번의 클릭으로 해지할 수 있습니다.

이번 주 소식 먼저 보기

매주 월요일 발송 · 구독 신청 시 확인 메일이 발송됩니다 · 수신거부는 모든 메일 하단에서 가능합니다.